pulmonx LUNG 深 滬
等待開盤 07-18 09:30:00 美东时间
3.09
+0.180
+6.19%
華盛通- 最 高3.31
- 今 開2.91
- 成交量 66.63万股
- 最 低 2.79
- 昨 收 2.91
- 總市值 1.24亿
- 52周最高 9.37
- 市盈率 靜 --
- 換手率 1.66%
- 52周最低 2.50
- 委 比 74.11%
- 總股本 4025.75万
- 歷史最高 69.478
- 量 比 1.05
- 振 幅 17.87%
- 歷史最低 2.50
- 每 手 1
- 風險率 2.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Pulmonx Corporation announced on July 16, 2025, that it will release its second-quarter 2025 financial results after market close on July 30, 2025. A conference call to discuss the results will follow at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Pulmonx investor website. Pulmonx is a global leader in minimally invasive lung disease treatments, offering products like the Zephyr® Endobronchial Valve for emphy...
07-16 20:05
bioAffinity Technologies Has Filed A New Patent Application Titled "DETECTION OF EARLY-STAGE LUNG CANCER IN SPUTUM USING AUTOMATED FLOW CYTOMETRY AND MACHINE LEARNING"
https://ppubs.uspto.gov/pubwebapp/external.html?q=(20250191706).pn
06-13 03:58
英飞凡在华获批成为首个且唯一*一个用于治疗局限期小细胞肺癌的免疫疗法
ADRIATIC III期试验结果显示与安慰剂相比，度伐利尤单抗可降低死亡风险27% 上海2025年6月4日 /美通社/ -- 阿斯利康今日宣布英飞凡®（通用名...
06-04 18:24
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Pulmonx Corporation will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast will be available on the Pulmonx website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), particularly for patients with severe emphysema. The company's products, including the FDA-approved Zephyr® Endobronch...
05-28 20:05
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
一周IPO | 梦回2020年港股打新牛市！宁德时代首日涨超16%；手回集团招股中
梦回2020年港股打新牛市！恒瑞医药首日飙升25%，宁德时代首日涨超16%；"小雨伞保险经纪母公司"手回集团招股中；派格生物医药、吉宏股份等预计下周上市>>
05-23 18:28
中金快讯 | 中金公司助力RNA诊断技术全球领先的新加坡企业Mirxes在香港联...
5月23日，Mirxes Holding Company Limited（以下简称“Mirxes”，股票代码：2629.HK）正式在香港联交所主板挂牌上市，发行...
05-23 17:21
交银国际助力Mirxes完成香港IPO项目
债券承销业务 5月23日，Mirxes Holding Company Limited（“Mirxes”，2629.HK）在香港联交所主板挂牌上市。Mirxe...
05-23 17:19
觅瑞正式登陆港交所：开盘上涨超30%，专注miRNA分子检测的全球化企业
全球范围内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。 据IPO早知道消息，Mirxes Holding Company Limited（以下简...
05-23 11:16
